AI Article Synopsis
- - A new biotherapy has been developed to effectively treat severe uncontrolled non-Th2 asthma.
- - In pulmonary arterial hypertension, starting patients on triple therapy from the time of diagnosis shows a survival advantage for high-risk individuals, with Riociguat offered to those at intermediate risk despite prior treatments.
- - Transbronchial cryobiopsies are emerging as a less invasive alternative to surgical lung biopsies for diagnosing diffuse interstitial lung diseases.
Article Abstract
Among the new therapeutic developments in pulmonology during 2021, we have identified three topics of interest. A new biotherapy is now available for the management of severe uncontrolled non-Th2 asthma. In the field of pulmonary arterial hypertension, upfront triple therapy at the time of diagnosis is associated with a survival benefit in high-risk patients. Riociguat is a therapeutic option for patients that remain at intermediate risk despite treatment with iPDE5. Sotatercept, a promising new class of drug for treatment of group 1 PAH will soon be available. Finally, the use of transbronchial cryobiopsies as a valid alternative to surgical lung biopsy for the diagnosis of diffuse interstitial lung diseases will also be discussed in this review.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2022.18.764-65.64 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!